GO
Loading...

Bayer AG

More

  • ABU DHABI, Jan 20- A plane powered by the sun will attempt an unprecedented flight around the world next month, the project's founders said, seeking to prove that flying is possible without using fossil fuel. Solar Impulse 2 is set to take off from Abu Dhabi with stopovers in India, Myanmar and China before crossing the Pacific Ocean and flying across the United...

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of an anticoagulant drug in a late-stage study, sending the company's shares up 11 percent in premarket trading. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto, developed by...

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • Nov 4- Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. Regeneron's net profit fell to $79.7 million, or 70 cents per share, in the third quarter ended Sept. 30 from $141.3 million, or $1.25 per share, a year earlier.

  • Nov 4- Regeneron Pharmaceuticals Inc reported a higher quarterly revenue on increased sales of its eye injection Eylea. The biotechnology company's net profit fell to $79.7 million, or 70 cents per share, in the third quarter Sept. 30, from $141.3 million, or $1.25 per share, a year earlier. Revenue rose 21.6 percent to $725.8 million and included collaboration...

  • UPDATE 1-FDA panel backs Daiichi's blood thinner Thursday, 30 Oct 2014 | 6:57 PM ET

    Oct 30- A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood thinner for use in some patients with atrial fibrillation. According to late-stage trial data submitted by Daiichi, the drug is as effective- and safer than- warfarin, an anticoagulant that has been on the market for more...

  • Oct 28- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein that plays a central role in...

  • Merck beats forecasts, as newer drugs offset generics Tuesday, 29 Jul 2014 | 10:39 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.

  • Big lobbying dollars flow in engineered food fight Tuesday, 29 Jul 2014 | 4:29 AM ET
    A researcher takes tissue samples from genetically modified corn plants.

    The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.

  • Merck proud to be a US-based company: CEO Wednesday, 4 Jun 2014 | 8:52 AM ET
    Ken Frazier, president and CEO of Merck.

    But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.

  • Early movers: WMT, GM, DTV, T & more Thursday, 15 May 2014 | 7:42 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Which M&A deal is best for shareholders? Monday, 12 May 2014 | 12:44 AM ET

    Which M&A deal represents the best value for shareholders?

  • Stocks fell Tuesday after American International Group reported a decline in profit.

  • Merck CEO on future M&A and taxes  Tuesday, 6 May 2014 | 11:16 AM ET

    Merck CEO Kenneth Frazier speaks with CNBC hours after announcing a blockbuster deal with Bayer.

  • Merck CEO done great job: Cramer  Tuesday, 6 May 2014 | 9:11 AM ET

    Merck has agreed to sell its consumer care unit to Bayer for $14.2 million. The "Squawk on the Street" news team discuss the $14.2 billion price tag and product development.

  • U.S. stock index futures pointed to a flat open on Tuesday, ahead of several first-quarter earnings and trade data for March.

  • Early movers: MRK, GE, DTV, AIG, APC, CS & more Tuesday, 6 May 2014 | 7:54 AM ET
    Traders on the floor of the New York Stock Exchange on April 11, 2014

    Some of the names on the move ahead of the open.

  • Aspirin and suntan lotion? Bayer, Merck do deal Tuesday, 6 May 2014 | 7:13 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.